Silja Chouquet examines the Twitter noise at pharma meetings and offers pointers to keep KOLs engaged while avoiding the attention of worthless click-farm accounts.
Pharma companies which embrace social media can reap many benefits beyond marketing, but they must be aware of the regulations and keep within guidelines to avoid heavy penalties.
After five years writing the regular Pharma Gets Social column for pharmaphorum, Daniel Ghinn introduces his new series entitled "What doctors say about...".
In its bid to satisfy investors with returns on paid advertising, Twitter is damaging genuine engagement, while pharma's buying power is quoshing the opportunity for balanced conversations, say
